Impact of Statins on Prostate Cancer and PSA Levels
Author Information
Author(s): Alkiviadis Papagiannakis, Maciej Kwiatkowski, Stephen F. Wyler, Ashkan Mortezavi, Lukas Manka, Marian S. Wettstein, Rainer Grobholz, Angelika Hammerer‐Lercher, Daniel Eberli, Lukas Werner Prause
Primary Institution: Department of Urology Cantonal Hospital Aarau
Hypothesis
Does regular statin intake affect prostate-specific antigen values, prostate cancer incidence, and overall survival?
Conclusion
Statin use was associated with lower PSA values but did not reduce the risk of developing prostate cancer and was linked to a higher overall mortality risk.
Supporting Evidence
- Statin users had significantly lower PSA values at baseline and follow-up.
- PCa incidence was similar between statin users and non-users.
- Statin use was associated with a higher overall mortality risk.
Takeaway
Taking statins might lower a blood test number called PSA, but it doesn't help prevent prostate cancer and could make people more likely to die from other causes.
Methodology
A population-based cohort study evaluated 4,314 men, comparing PSA levels and prostate cancer incidence between statin users and non-users over a median follow-up of 9.6 years.
Potential Biases
Healthy user bias may exist as statin users tend to be older and have more comorbidities.
Limitations
The study lacked data on statin type and dosage, and potential confounding factors such as comorbidities and lifestyle factors were not controlled.
Participant Demographics
Men aged 55-70 years, with 761 statin users and 3553 non-users.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI 1.55–2.69
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website